Abstract:
:Depressive symptoms are associated with poor outcomes, increased risk of relapse, and high suicide rates in patients with schizophrenia and schizoaffective disorder. This randomized, open-label, parallel-group, flexible-dose study (NCT00640562) assessed the efficacy of quetiapine extended release (XR) versus risperidone on depressive symptoms in this patient population. Noninferiority of quetiapine XR versus risperidone from baseline to week 12 was assessed by least squares mean (LSM) reduction in the Calgary Depression Scale for Schizophrenia (CDSS). Noninferiority was indicated if the difference in CDSS reductions between quetiapine XR and risperidone had a 95% confidence interval (CI) lower limit of more than -2.7. Overall, 216 patients received quetiapine XR (n = 109; 400-800 mg/day) or risperidone (n = 107; 4-6 mg/day). In the per-protocol population, LSM CDSS reductions for quetiapine XR and risperidone were 8.4 and 6.2 points, respectively (95% CI 0.8-3.7). As the lower limit of the 95% CI was more than -2.7 and the LSM reduction for quetiapine XR was 2.2 points higher than that for risperidone, noninferiority of quetiapine XR versus risperidone was demonstrated. Adverse events for quetiapine XR and risperidone were comparable. In this study, quetiapine XR was noninferior to risperidone at reducing depressive symptoms in patients with schizophrenia or schizoaffective disorder.
journal_name
Int Clin Psychopharmacoljournal_title
International clinical psychopharmacologyauthors
Di Fiorino M,Montagnani G,Trespi G,Kasper Sdoi
10.1097/YIC.0000000000000017subject
Has Abstractpub_date
2014-05-01 00:00:00pages
166-76issue
3eissn
0268-1315issn
1473-5857pii
00004850-201405000-00005journal_volume
29pub_type
杂志文章,多中心研究,随机对照试验abstract::Paroxetine has been characterized as a highly potent and selective 5-hydroxytryptamine (serotonin) reuptake inhibitor. This selectivity has been demonstrated not only for monoamine uptake mechanisms but also for neurotransmitter receptor systems. The pharmacokinetic studies indicate that paroxetine may be administered...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:
更新日期:1992-06-01 00:00:00
abstract::We report a case of myoclonus induced by quetiapine. A 64-year-old man with schizophrenia developed myoclonic jerks when given higher doses of quetiapine. These movements were dose-related and completely abated on reducing the dose. To our knowledge, these movements have not been reported previously as an adverse effe...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-200503000-00011
更新日期:2005-03-01 00:00:00
abstract::Nocturnal eating/drinking syndrome secondary to neuroleptic-induced restless legs syndrome (RLS) occurred under treatment with low-dose haloperidol in a 51-year-old female schizophrenic patient. Polysomnographic investigation showed a low level of sleep efficacy, periodic leg movements, and a strict relationship betwe...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:1999-01-01 00:00:00
abstract::A review of published evidence of superior efficacy of a particular antidepressant in major depressive disorder may assist clinicians in making considered treatment choices. To identify such candidates, an international group of experts met to assess published evidence (identified through searches in Medline and Embas...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/YIC.0b013e3282eff7e0
更新日期:2007-11-01 00:00:00
abstract::The chronic course of major depressive disorder (MDD) often impedes the ability of patients to achieve full remission. Return of full functioning is a critical goal of antidepressant pharmacotherapy as the presence of residual depressive symptoms is associated with an increased risk of relapse. Treatment guidelines re...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,meta分析
doi:10.1097/YIC.0000000000000121
更新日期:2016-05-01 00:00:00
abstract::Severe orthostatic and cardiorespiratory dysregulation may occur during institution of clozapine therapy both during concomitant benzodiazepine medication and on reinstitution of clozapine after a washout period. Extensive medical and neurological workup before and after the trials can nevertheless be normal. The abse...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-199300830-00012
更新日期:1993-10-01 00:00:00
abstract::Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin and norepinephrine reuptake inhibitor that is Food and Drug Administration approved for once-daily treatment of major depressive disorder in adults. Secondary and post-hoc analyses were carried out on data from a positive 10-week, randomized, dou...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/YIC.0000000000000009
更新日期:2014-01-01 00:00:00
abstract::Recent evidence has demonstrated the efficacy of pegylated interferon-alpha (IFN-alpha) in treating hepatitis C virus infection. Neuropsychiatric complications commonly occur during the course of IFN treatment, with depressive symptoms usually appearing within the first 12 weeks. Few cases of the pegylated interferon-...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/01.yic.0000170263.46008.54
更新日期:2005-09-01 00:00:00
abstract::On the basis of numerous previous studies, the serotonergic system plays a role in the pathogenesis of obsessive-compulsive disorder (OCD) and effective agents in this pathway, such as 5-hydroxytryptophan, can potentially contribute to treatment of patients with this disorder. Evaluating the efficacy of 5-hydroxytrypt...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/YIC.0000000000000321
更新日期:2020-09-01 00:00:00
abstract::Arrhythmias are a frequent and potentially fatal side effect of antipsychotic treatment. Strict ECG monitoring and clinical interviews are the standards used to prevent arrhythmias. A biologic predictive tool is missing. The identification of a genetic makeup at risk of antipsychotic-induced arrhythmias is the aim of ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/YIC.0000000000000198
更新日期:2018-01-01 00:00:00
abstract::A group of 13 untreated schizophrenic patients was collected over two and a half years. They were prescribed a standard regime of oral haloperidol, and where possible were transferred to haloperidol decanoate depot injections when their clinical condition stabilised. The progress of their symptoms was monitored weekly...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:
更新日期:1986-07-01 00:00:00
abstract::C-reactive protein (CRP) is an inflammatory marker associated with obesity, insulin resistance, and cardiovascular disease. A recent study found CRP levels to be higher in individuals treated with certain antipsychotic medications such as olanzapine; however, it is not clear whether this is associated directly with dr...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0b013e3283400cd3
更新日期:2011-01-01 00:00:00
abstract::Benzodiazepines are commonly used for behavioral and psychiatric symptoms of dementia, despite their numerous adverse effects and the lack of evidence regarding their efficacy in this context. We studied longitudinal benzodiazepines exposure in incident cases of Alzheimer's disease and related syndromes (ADRS) in Fran...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000312
更新日期:2020-09-01 00:00:00
abstract::The primary objective of this post-hoc analysis was to evaluate the effect of short-term treatment with desvenlafaxine versus placebo on sexual dysfunction (SD), assessed from Arizona Sexual Experiences Scale scores, in adult outpatients with major depressive disorder. Data from three randomized, double-blind, placebo...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000094
更新日期:2015-11-01 00:00:00
abstract::There is uncertainty with regard to the appropriate use of metformin for the prevention and management of second-generation antipsychotic-induced weight gain and metabolic abnormalities. We aim to systematically review the primary literature and to provide recommendations with regard to the use of metformin in psychia...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/YIC.0b013e32834d0a5b
更新日期:2012-03-01 00:00:00
abstract::This study is aimed at investigating the efficacy and tolerability of mirtazapine in a generalized social anxiety disorder. Sixty patients with generalized social anxiety disorder were randomly allocated to receive mirtazapine (30-45 mg/day) (n= 30) or placebo (n= 30) for 12 weeks in a double-blind study design. Prima...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/yic.0b013e32833a4d71
更新日期:2010-09-01 00:00:00
abstract::Since the introduction in 1993 of the novel serotonin-dopamine antagonist antipsychotic risperidone, over 12 million patient-months of exposure to the drug have been accumulated. Further studies have confirmed the efficacy of risperidone across a broad range of patients with schizophrenia who were not represented in t...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:
更新日期:1997-09-01 00:00:00
abstract::Hematological indices were measured in 8 patients with bipolar disorder during carbamazepine and carbamazepine-lithium combination treatment. Carbamazepine treatment was associated with limited reductions in white blood cell indices. Combined lithium-carbamazepine treatment reversed the reductions in total white cell ...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-198801000-00004
更新日期:1988-01-01 00:00:00
abstract::The effect of the antipsychotic drug trifluoperazine (TFP) on the in-vitro growth of 50 clinical isolates of Mycobacterium tuberculosis was tested. Of these isolates, 29 were susceptible to all five of the antitubercular drugs isoniazid, rifampicin, streptomycin, ethambutol and pyrazinamide, and 21 were resistant to o...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-199805000-00006
更新日期:1998-05-01 00:00:00
abstract::Social phobia and avoidant personality disorder were new diagnoses in the third version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) and were considerably changed in the revised third version (DSM-III-R). A high rate of comorbidity between these disorders was observed, which can be explained ...
journal_title:International clinical psychopharmacology
pub_type:
doi:
更新日期:1996-06-01 00:00:00
abstract::The purpose of this study was to compare the efficacy and safety of risperidone and haloperidol in treatment-resistant chronic schizophrenic patients. Subjects (n = 78) who met DSM-III criteria for schizophrenia were randomly assigned to receive 6 mg/day of risperidone or 20 mg/day of haloperidol for 12 weeks. Clinica...
journal_title:International clinical psychopharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00004850-200111000-00002
更新日期:2001-11-01 00:00:00
abstract::Treatments given to patients with primary psychotic disorders include mood stabilizers (MSs) combined with other psychotropics, despite the limited evidence of efficacy, safety, and lack of regulatory approval. We analyzed records of 636 inpatients at the McLean Hospital (2002-2009), who were diagnosed with bipolar di...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0b013e328340c0de
更新日期:2011-03-01 00:00:00
abstract::Thirty healthy subjects 12 males and 18 females were given the acetylcholinesterase inhibitor pyridostigmine (120 mg) orally. The growth hormone (GH) response was measured as the maximum GH level post-pyridostigmine relative to baseline. Twenty-six subjects increased their GH level in response to pyridostigmine. Respo...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-199100620-00005
更新日期:1991-07-01 00:00:00
abstract::Medication adherence with antipsychotics is adversely impacted by the burden of untoward adverse effects. In particular, sexual side-effects may interfere with compliance, but are often underreported by patients. Sexual dysfunction related to hyperprolactinemia is commonly described, but ejaculatory disturbance due to...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/00004850-200403000-00009
更新日期:2004-03-01 00:00:00
abstract::Several cardiovascular risk factors have been linked to antipsychotic treatment and cardiovascular mortality is increased in these patients compared to the general population. The full metabolic syndrome (or its components) is associated with an increased risk of cardiovascular disorders. The prevalence of the metabol...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/01.yic.0000188215.84784.17
更新日期:2006-03-01 00:00:00
abstract::The interactions between warfarin and antidepressants can have potentially serious consequences resulting from enhanced or reduced anticoagulant activity. Information about such interactions was obtained from a Medline and hand search of the published literature, and by directly contacting manufacturers. The different...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:10.1097/00004850-199803000-00006
更新日期:1998-03-01 00:00:00
abstract::A variety of cognitive impairments can be observed in patients with schizophrenia, including substantial reductions in the intelligence quotient (IQ). I propose that these impairments can be best understood in terms of the abnormal processes underlying the signs and symptoms manifested by the patient at the time of th...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,评审
doi:
更新日期:1995-09-01 00:00:00
abstract::Mood stabilizers are used clinically for the management of bipolar disorder. Prophylactic therapy with mood stabilizers is the primary treatment for preventing depressive and manic relapses in bipolar patients once they are stabilized. In this study, we examined the relative efficacy of the three most commonly used mo...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章
doi:10.1097/YIC.0000000000000097
更新日期:2016-07-01 00:00:00
abstract::The present study aimed to compare health outcomes and tolerability according to antipsychotic medication (olanzapine, risperidone or an oral typical antipsychotic) after 6 months of treatment in a group of 919 schizophrenic patients who had never previously been treated with antipsychotics. Demographic and clinical p...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,多中心研究
doi:10.1097/00004850-200507000-00002
更新日期:2005-07-01 00:00:00
abstract::The use of certain atypical antipsychotics has been associated with metabolic disturbances. We have assessed the evolution of body weight and glycaemia during a 6-month randomized comparative trial of amisulpride and olanzapine. Three hundred and seventy-seven adult patients with schizophrenia were randomized to eithe...
journal_title:International clinical psychopharmacology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1097/YIC.0b013e3280148c29
更新日期:2007-05-01 00:00:00